Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study.
COVID-19
bleeding
extracorporeal membrane oxygenation
mortality
thrombosis
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
17
09
2021
received:
24
08
2021
accepted:
19
09
2021
pubmed:
9
10
2021
medline:
2
2
2022
entrez:
8
10
2021
Statut:
ppublish
Résumé
Bleeding and thrombosis are major complications in patients supported with extracorporeal membrane oxygenation (ECMO). In this multicentre observational study of 152 consecutive patients (≥18 years) with severe COVID-19 supported by veno-venous (VV) ECMO in four UK commissioned centres during the first wave of the COVID-19 pandemic (1 March to 31 May 2020), we assessed the incidence of major bleeding and thrombosis and their association with 180-day mortality. Median age (range) was 47 years (23-65) and 75% were male. Overall, the 180-day survival was 70·4% (107/152). The rate of major bleeding was 30·9% (47/152), of which intracranial bleeding (ICH) was 34% (16/47). There were 96 thrombotic events (63·1%) consisting of venous 44·7% [68/152 of which 66·2% were pulmonary embolism (PE)], arterial 18·6% (13/152) and ECMO circuit thrombosis 9·9% (15/152). In multivariate analysis, only raised lactate dehydrogenase (LDH) at the initiation of VV ECMO was associated with an increased risk of thrombosis [hazard ratio (HR) 1·92, 95% CI 1·21-3·03]. Major bleeding and ICH were associated with 3·87-fold (95% CI 2·10-7·23) and 5·97-fold [95% confidence interval (CI) 2·36-15·04] increased risk of mortality and PE with a 2·00-fold (95% CI1·09-3·56) risk of mortality. This highlights the difficult balancing act often encountered when managing coagulopathy in COVID-19 patients supported with ECMO.
Identifiants
pubmed: 34622443
doi: 10.1111/bjh.17870
pmc: PMC8653259
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
566-576Subventions
Organisme : Bayer Public limited company
ID : P87339
Informations de copyright
© 2021 British Society for Haematology and John Wiley & Sons Ltd.
Références
Intensive Care Med. 2020 Oct;46(10):1932-1933
pubmed: 32377767
Autoimmun Rev. 2020 Jul;19(7):102569
pubmed: 32376394
Thromb J. 2021 May 19;19(1):32
pubmed: 34011381
Crit Care. 2020 Jul 27;24(1):464
pubmed: 32718343
Br J Haematol. 2020 Sep;190(5):e286-e288
pubmed: 32516429
J Thromb Haemost. 2016 Nov;14(11):2253-2260
pubmed: 27601054
Crit Care Med. 2020 May;48(5):e371-e379
pubmed: 32058356
Lancet. 2020 Oct 10;396(10257):1071-1078
pubmed: 32987008
N Engl J Med. 2021 Aug 26;385(9):777-789
pubmed: 34351722
ASAIO J. 2017 Jan/Feb;63(1):60-67
pubmed: 27984321
Front Pharmacol. 2020 Aug 21;11:1307
pubmed: 32973526
Res Pract Thromb Haemost. 2020 Oct 13;4(7):1178-1191
pubmed: 33043231
ASAIO J. 2021 May 1;67(5):485-495
pubmed: 33657573
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Lancet Respir Med. 2021 Feb;9(2):e16-e17
pubmed: 33428874
Crit Care Med. 2021 Jul 1;49(7):e663-e672
pubmed: 33861545
Am J Respir Crit Care Med. 2020 Sep 1;202(5):690-699
pubmed: 32667207
Semin Thromb Hemost. 2018 Apr;44(3):276-286
pubmed: 29566407
J Intensive Care. 2020 Jul 10;8:49
pubmed: 32665858
Crit Care Med. 2020 Jun;48(6):e440-e469
pubmed: 32224769
J Med Vasc. 2020 Sep;45(5):268-274
pubmed: 32862984
Lancet Respir Med. 2020 Nov;8(11):1121-1131
pubmed: 32798468
JAMA. 2011 Oct 19;306(15):1659-68
pubmed: 21976615
BMC Res Notes. 2020 Dec 9;13(1):555
pubmed: 33298124